Human Clinical Trial Begins For Texas A&M-Discovered Drug To Treat Angelman Syndrome
Developed by biopharmaceutical company Ultragenyx, GTX-102 is the first clinically developed drug targeting the genetic causes of Angelman syndrome rather than symptoms. Dr. Scott Dindot, photos by Jason Nitsch ’14, VMBS Marketing & Communications The first therapeutic drug for Angelman syndrome (AS) — discovered by Texas A&M researchers — has begun human trials, bringing it […]
SHARE